Proteomics and recurrence of atrial fibrillation: a pilot study nested in the PREDIMAR trial

Date

2025-01-24

Authors

Razquin, Cristina
Barrio-López, María Teresa
López, Begoña
Ravassa, Susana
Ramos, Pablo
Macías-Ruiz, Rosa
Ibáñez Criado, Alicia
Goñi, Leticia

Director

Publisher

Karger
Acceso abierto / Sarbide irekia
Artículo / Artikulua
Versión publicada / Argitaratu den bertsioa

Project identifier

  • ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F00718/ES/ recolecta
  • ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F00748/ES/ recolecta
  • ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F01870/ES/ recolecta
  • Gobierno de Navarra///
Impacto
OpenAlexGoogle Scholar
cited by count

Abstract

Introduction: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide. Although catheter ablation is the most efficacious therapy, relapses occur frequently (30%) in the first year after ablation. Novel biomarkers of recurrence are needed for a better prediction of recurrence and management of AF. In this pilot study, we aimed to analyze the baseline proteome of subjects included in a case-control study to find differential proteins associated with AF recurrence. Methods: Baseline serum proteomics (354 proteins) data from 16 cases (recurrent AF) and 17 controls (non-recurrent) were obtained using MS/MS analysis. A false discovery rate was performed using a nonlinear fitting method for the selection of proteins. Logistic regression models were used to further analyze the association between differentially expressed proteins and AF recurrence. Results: Ten proteins were differentially represented in cases vs. controls. Two were upregulated in the cases compared to the controls: keratin type I cytoskeletal 17 (Fold-change [FC] = 2.14; p = 0.017) and endoplasmic bifunctional protein (FC = 1.65; p = 0.032). Eight were downregulated in the cases compared to the controls: C4bpA (FC = 0.64; p = 0.006), coagulation factor XI (FC = 0.83; p = 0.011), CLIC1 (FC = 0.62; p = 0.017), haptoglobin (FC = 0.37; p = 0.021), Ig alpha-2 chain C region (FC = 0.49; p = 0.022), C4bpB (FC = 0.73; p = 0.028), N-acetylglucosamine-1- phosphotransferase subunit gamma (FC = 0.61; p = 0.033), and platelet glycoprotein Ib alpha chain (FC = 0.84; p = 0.038). Conclusion: This pilot study identifies ten differentially expressed serum proteins associated with AF recurrence, offering potential biomarkers for improved prediction and management.

Description

Keywords

Proteomics, Atrial fibrillation, Recurrence, PREDIMAR

Department

Ciencias de la Salud / Osasun Zientziak

Faculty/School

Degree

Doctorate program

item.page.cita

Razquin, C., Fernández-Irigoyen, J., Barrio-López, M. T., López, B., Ravassa, S., Ramos, P., Macías-Ruiz, R., Ibañez Criado, A., Santamaría, E., Goni, L., Castellanos, E., Ibáñez Criado, J. L., Tercedor, L., García-Bolao, I., Martínez-González, M. A., Almendral, J., Ruiz-Canela, M. (2025) Proteomics and recurrence of atrial fibrillation: a pilot study nested in the PREDIMAR trial. Lifestyle Genomics, 18(1), 52-58. https://doi.org/10.1159/000543639.

item.page.rights

© 2025 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons AttributionNonCommercial 4.0 International License (CC BY-NC), usage and distributionfor commercial purposes requires written permission.

Licencia

Los documentos de Academica-e están protegidos por derechos de autor con todos los derechos reservados, a no ser que se indique lo contrario.